- Home
- WHLR vs TNFA Comparison
WHLR vs TNFA Comparison
Compare WHLR & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHLR
- TNFA
- Stock Information
- Founded
- WHLR 2011
- TNFA 2014
- Country
- WHLR United States
- TNFA United States
- Employees
- WHLR N/A
- TNFA N/A
- Industry
- WHLR Real Estate Investment Trusts
- TNFA
- Sector
- WHLR Real Estate
- TNFA
- Exchange
- WHLR Nasdaq
- TNFA NYSE
- Market Cap
- WHLR 1.5M
- TNFA 1.6M
- IPO Year
- WHLR 2012
- TNFA N/A
- Fundamental
- Price
- WHLR $5.81
- TNFA $0.11
- Analyst Decision
- WHLR
- TNFA
- Analyst Count
- WHLR 0
- TNFA 0
- Target Price
- WHLR N/A
- TNFA N/A
- AVG Volume (30 Days)
- WHLR 2.9M
- TNFA 4.8M
- Earning Date
- WHLR 08-05-2025
- TNFA 08-18-2025
- Dividend Yield
- WHLR N/A
- TNFA N/A
- EPS Growth
- WHLR N/A
- TNFA N/A
- EPS
- WHLR N/A
- TNFA N/A
- Revenue
- WHLR $102,793,000.00
- TNFA N/A
- Revenue This Year
- WHLR N/A
- TNFA N/A
- Revenue Next Year
- WHLR N/A
- TNFA N/A
- P/E Ratio
- WHLR N/A
- TNFA N/A
- Revenue Growth
- WHLR 0.86
- TNFA N/A
- 52 Week Low
- WHLR $3.33
- TNFA $0.10
- 52 Week High
- WHLR $10,567.20
- TNFA $2.16
- Technical
- Relative Strength Index (RSI)
- WHLR 48.32
- TNFA 32.59
- Support Level
- WHLR $5.65
- TNFA $0.11
- Resistance Level
- WHLR $6.40
- TNFA $0.14
- Average True Range (ATR)
- WHLR 0.93
- TNFA 0.02
- MACD
- WHLR 0.21
- TNFA 0.00
- Stochastic Oscillator
- WHLR 11.09
- TNFA 12.04
About WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.